DOH seeks UP-PGH help to validate Dengvaxia-linked deaths | Inquirer

DOH seeks UP-PGH help to validate Dengvaxia-linked deaths

/ 02:05 PM December 21, 2017

The Department of Health (DOH) said on Thursday that it sought the help of experts from the University of the Philippines-Philippine General Hospital (UP-PGH) to validate the alleged deaths among children immunized with Dengvaxia.

“We are being transparent to erase doubts from other sectors that the DOH may be concealing information relevant to Dengvaxia vaccination,” said Health Secretary Francisco Duque III in a press briefing.

UP-PGH would be providing an independent review and assessment on the probable cause of deaths of the children submitted by the DOH through an expert group of pediatricians, pathologists, and other specialists with no financial or intellectual ties to Sanofi Pasteur, the French drug manufacturer of Dengvaxia.

Article continues after this advertisement

At least two deaths of 10-year-old girls from Bataan and Quezon City have so far been reported and linked to the Dengvaxia vaccine. Their families claimed the children died after getting vaccinated in school.

Duque reiterated that the DOH remains open to any inquiry and has, in fact, been cooperating with authorities on the investigation of Dengvaxia procurement and alleged deaths due to the vaccine.                             /kga

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

EDITORS' PICK
entertainment
entertainment
usa
sports
business
business
TAGS: Children, Dengvaxia, DoH, Health, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2024 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.